Dr Li Xugang

Radiation Oncologist

Dr Li Xugang is committed to increasing general knowledge of radiation therapy treatments to help raise awareness of this widely-used and effective cancer treatment. Throughout his practice, he continues to combine the latest radiation therapy technology with other proven forms of treatment to ensure cancer treatment in China continues to evolve and more people can access the best possible care. He is passionate about listening and learning with a commitment to offering the most caring support through understanding the feelings of his patients, and takes great joy in relieving any pain experienced by patients.

  • Fengcheng
Become a Patient

Biography

Dr Li Xugang graduated from the Jinzhou Medical University in 1985, before commencing further study from 1989-1990 and undertaking training in the Department of Radiotherapy, Beijing Cancer Hospital, Chinese Academy of Medical Sciences.

He later became Director of the Radiation Therapy Department within the Anshan Cancer Hospital. With more than 30 years’ of clinical expertise, Dr Li Xugang specialises in image diagnosis of cancer and highly-accurate radiation therapy treatment.

Affiliations & Memberships

  • Visiting Professor at Soohcow University
  • Chinese Radiation Therapy Oncology Group
  • Standing committee of CRTOG Radiation Immune Working Committee of Liaoning branch
  • China North Radiotherapy Group member
  • The seventh session of standing committee of Tumor Radiation Therapy Association in Liaoning Province
  • The third session of standing committee of Radiotherapy Association of LACA
  • Director Committee of Anshan Oncology Quality Control Expert Association

Special Interests

Dr Li Xugang accepts referrals for all cancer types, with a special clinical interest in:
  • Colorectal cancer
  • Lung cancer
  • Prostate cancer
  • Stomach cancer

Icon Locations

Fengcheng View centre

Publications

  • Metabolomic Analysis of Radiation-Induced Lung Injury in Rats: The Potential Radioprotective Role of Taurine – Dose-Response:An International Journal,October-December 2019:1-11

     

  • The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells- Drug Design, Development and Therapy 2020:14 3099–3110

  • The progeny of carbon-irradiated glioma cells do not cause obvious medium-mediated non-targeted effects in neural stem cells – in publication process